En fase 2b, undersøgelse, der evaluerer Miricorilant hos voksne patienter med ikke-alkoholisk Steatohepatitis (MONARCH)
En fase 2b, randomiseret, dobbeltblind, placebokontrolleret undersøgelse, der evaluerer effektiviteten og sikkerheden af Miricorilant hos voksne patienter med ikke-alkoholisk Steatohepatitis (MONARCH)
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Miricorilant in Adult Patients with Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Approximately 75 patients who are eligible for participation in the study will be randomized on Day 1 in a 2:1 ratio to 100 mg miricorilant or placebo twice weekly, for 48 weeks of treatment (Cohort A).
Approximately 90 patients who are eligible for participation in the study will be randomized on Day 1 in a 2:1 ratio to 100 mg miricorilant twice a week for 6 weeks of treatment, followed by a dose escalation to 200 mg miricorilant or placebo twice weekly for an additional 18 weeks which resulting in a total treatment duration of 24 weeks, or to placebo for 24 weeks. (Cohort B).
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
Arizona
-
Chandler, Arizona, Forenede Stater, 85224
- Site #207
-
Tucson, Arizona, Forenede Stater, 85712
- Site #209
-
-
California
-
Huntington Park, California, Forenede Stater, 90255
- Site #378
-
Lancaster, California, Forenede Stater, 93534
- Site #439
-
Long Beach, California, Forenede Stater, 90815
- Site #469
-
Los Angeles, California, Forenede Stater, 90056
- Site #373
-
Panorama City, California, Forenede Stater, 91402
- Site #214
-
Santa Ana, California, Forenede Stater, 92704
- Site #233
-
-
Florida
-
Boca Raton, Florida, Forenede Stater, 33434
- Site #452
-
Gainesville, Florida, Forenede Stater, 32610
- Site # 101
-
Hallandale, Florida, Forenede Stater, 33009
- Site #465
-
Hialeah Gardens, Florida, Forenede Stater, 33016
- Site #430
-
Lakewood Rch, Florida, Forenede Stater, 38018
- Site #458
-
Largo, Florida, Forenede Stater, 33777
- Site #475
-
Miami Lakes, Florida, Forenede Stater, 33016
- Site #438
-
Viera, Florida, Forenede Stater, 32940
- Site #460
-
-
Louisiana
-
Houma, Louisiana, Forenede Stater, 70363
- Site #453
-
Marrero, Louisiana, Forenede Stater, 70072
- Site #451
-
Metairie, Louisiana, Forenede Stater, 70006
- Site #061
-
-
Maryland
-
Rockville, Maryland, Forenede Stater, 20854
- Site #440
-
-
Minnesota
-
Saint Paul, Minnesota, Forenede Stater, 55114
- Site #442
-
-
Missouri
-
Kansas City, Missouri, Forenede Stater, 64131
- Site #228
-
-
New Jersey
-
Jackson, New Jersey, Forenede Stater, 08724
- Site #455
-
-
New York
-
East Syracuse, New York, Forenede Stater, 13057
- Site #445
-
New York, New York, Forenede Stater, 10033
- Site #454
-
-
North Carolina
-
Morehead City, North Carolina, Forenede Stater, 29557
- Site #464
-
-
Ohio
-
Beavercreek, Ohio, Forenede Stater, 45440
- Site #447
-
Columbus, Ohio, Forenede Stater, 43234
- Site #470
-
Dayton, Ohio, Forenede Stater, 45145
- Site #448
-
Westlake, Ohio, Forenede Stater, 44145
- Site #437
-
-
Tennessee
-
Cordova, Tennessee, Forenede Stater, 38018
- Site #461
-
-
Texas
-
Arlington, Texas, Forenede Stater, 76012
- Site # 546
-
Austin, Texas, Forenede Stater, 78756
- Site #545
-
Austin, Texas, Forenede Stater, 78757
- Site #211
-
Brownsville, Texas, Forenede Stater, 78520
- Site #432
-
Dallas, Texas, Forenede Stater, 75230
- Site #370
-
Edinburg, Texas, Forenede Stater, 78539
- Site #213
-
Edinburg, Texas, Forenede Stater, 78539
- Site #215
-
Georgetown, Texas, Forenede Stater, 78626
- Site #431
-
Houston, Texas, Forenede Stater, 77030
- Site # 066
-
Houston, Texas, Forenede Stater, 77079
- Site #305
-
Katy, Texas, Forenede Stater, 77494
- Site #459
-
San Antonio, Texas, Forenede Stater, 78125
- Site #433
-
San Antonio, Texas, Forenede Stater, 78229
- Site #212
-
Waco, Texas, Forenede Stater, 78125
- Site #434
-
-
Utah
-
West Jordan, Utah, Forenede Stater, 84088
- Site #441
-
-
Virginia
-
Manassas, Virginia, Forenede Stater, 20110
- Site #463
-
-
Washington
-
Seattle, Washington, Forenede Stater, 98105
- Site #226
-
-
-
-
-
New Delhi, Indien, 110029
- Site #482
-
New Delhi, Indien, 110060
- Site #510
-
New Delhi, Indien, 110070
- Site #501
-
-
Assam
-
Guwahati, Assam, Indien, 781032
- Site #506
-
-
Gujarat
-
Ahmedabad, Gujarat, Indien, 380053
- Site #492
-
Rajkot, Gujarat, Indien, 360001
- Site #513
-
Surat, Gujarat, Indien, 395009
- Site #490
-
Surat, Gujarat, Indien, 395009
- Site #514
-
Vadodara, Gujarat, Indien, 390007
- Site #502
-
-
Haryana
-
Rohtak, Haryana, Indien, 124001
- Site # 494
-
-
Karnataka
-
Mysore, Karnataka, Indien, 570015
- Site #511
-
-
Kerala
-
Thiruvananthapuram, Kerala, Indien, 695011
- Site #507
-
-
Maharashtra
-
Mumbai, Maharashtra, Indien, 400008
- Site #512
-
Mumbai, Maharashtra, Indien, 400062
- Site #509
-
Nagpur, Maharashtra, Indien, 440009
- Site #500
-
Pune, Maharashtra, Indien, 412201
- Site #496
-
-
Punjab
-
Ludhiana, Punjab, Indien, 141002
- Site #495
-
-
Rajasthan
-
Jaipur, Rajasthan, Indien, 302001
- Site #489
-
Jaipur, Rajasthan, Indien, 302004
- Site # 485
-
-
Tamil Nadu
-
Madurai, Tamil Nadu, Indien, 625020
- Site #508
-
-
Telangana
-
Hyderabad, Telangana, Indien, 500003
- Site #486
-
-
Uttar Pradesh
-
Lucknow, Uttar Pradesh, Indien, 226003
- Site #549
-
Varanasi, Uttar Pradesh, Indien, 221005
- Site #488
-
Varanasi, Uttar Pradesh, Indien, 221005
- Site #503
-
-
Uttarakhand
-
Dehradun, Uttarakhand, Indien, 248001
- Site #504
-
-
West Bengal
-
Kolkata, West Bengal, Indien, 700020
- Site #487
-
Kolkata, West Bengal, Indien, 700073
- Site #493
-
Kolkata, West Bengal, Indien, 700150
- Site #491
-
-
-
-
-
San Juan, Puerto Rico, 00927-4807
- Site #457
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
Cohort A: Histological diagnosis of NASH/MASH with NAS ≥ 4 (≥ 1 point in each subcomponent of steatosis, inflammation, and ballooning) and NASH-CRN fibrosis score of 2 or 3 based on the consensus method of histological assessment. A historical liver biopsy within 6 months of Screening with reading confirmed during the Screening period by a consensus panel is acceptable.
-
Cohort B: Have a liver biopsy result that does not meet with the criteria for inclusion in Cohort A and is consistent with one of the following based on the consensus method of histological assessment:
- NAS ≥ 3 with ≥1 point in each subcomponent of steatosis, inflammation, and ballooning, and a NASH-CRN fibrosis score of F1 or
- NAS ≥ 2 with ≥1 point in subcomponent of steatosis and ≥ 1 point in subcomponent of ballooning or inflammation and a NASH-CRN fibrosis score of F2 or 3
-
AST > 17 U/L for women and AST > 20 U/L for men.
-
FibroScan® liver stiffness measurement ≥ 8 kPa and CAP ≥ 280 dB/m.
-
MRI-PDFF with ≥ 8% steatosis
-
Presence of at least 1 of the following metabolic syndromes that increase the risk of NASH/MASH:
- Diagnosis of type 2 diabetes OR
- Presence of 2 or more components of metabolic syndrome:
i. Fasting blood glucose ≥ 100 mg/dL (5.6 mmol/L) or treatment for elevated blood glucose ii. Systolic blood pressure ≥ 130mmHg, diastolic blood pressure ≥ 85mmHg, or treatment for hypertension iii. Serum triglycerides ≥ 150 mg/dL (1.7 mmol/L) or drug treatment for elevated triglycerides iv. Serum high-density lipoprotein (HDL) cholesterol < 40 mg/dL (1 mmol/L) in men and < 50 mg/dL (1.3 mmol/L) in women or drug treatment for low HDL v. Overweight or obese (body mass index [BMI] ≥ 25 kg/m2 [BMI ≥ 23 kg/m2 in Asians]), or increased waist circumference ≥ 102 cm (40 in) in men and ≥ 88 cm (35 in) in women (male ≥ 90 cm [35.4 in]; women ≥ 80 cm [31.5 in] in
-
Other inclusion criteria may apply
Exclusion Criteria:
- Have participated in another clinical trial within the last 3 months of Screening where the patient received active treatment for NASH/MASH.
- Have participated in a clinical trial for any other indication within the last 3 months or 5 half-lives of the treatment, whichever is longer.
- Are pregnant or lactating women
- Have a BMI < 18 kg/m2 or > 45 kg/m2.• Have had liver transplantation or plan to have liver transplantation during the study
- Have type 1 diabetes or poorly controlled type 2 diabetes.
- Are pregnant or lactating women
- Have a BMI < 18 kg/m2 or > 45 kg/m2
- Have had successful weight-loss surgery within 2 years prior to Screening or are planning weight-loss surgery during the study.
- Have a >5% weight change within 3 months prior to Screening.
- Have significant alcohol consumption of more than 20 g per day for women and 30 g per day for men within 1 year prior to screening or score of ≥8 on AUDIT questionnaire
- Have any other chronic liver disease
- History of cirrhosis or evidence of cirrhosis by clinical, imaging, or liver biopsy evaluation
- Have hepatic decompensation
- Other exclusion criteria may apply
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Experimental (Cohort A)
Patients who meet the entry criteria for study CORT118335-862 (Cohort A) will be enrolled to receive 100 mg of miricorilant, twice a week for 48 weeks. |
Miricorilant 100 mg for oral dosing
Andre navne:
|
|
Placebo komparator: Placebo (Cohort A)
Patients who meet the entry criteria for study CORT118335-862 (Cohort A) will be enrolled to receive a matching placebo twice a week for 48 weeks. |
Matching placebo for oral dosing for 48 Weeks |
|
Placebo komparator: Placebo (Cohort B)
Patients who meet the entry criteria for study CORT118335-862 (Cohort B) will be enrolled to receive a matching placebo twice a week for 24 weeks. |
Matching placebo for oral dosing for 24 Weeks |
|
Eksperimentel: Experimental (Cohort B)
Patients who meet the entry criteria for study CORT118335-862 (Cohort B) will be enrolled to receive 100 mg of miricorilant, twice a week for 6 weeks. Dose will be escalated to 200 mg of miricorilant, twice a week for 18 weeks. |
Miricorilant 100 mg for oral dosing Miricorilant 200 mg for oral dosing
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Procent relativ ændring fra baseline i leverfedtindhold vurderet ved MRI-PDFF (kohorte A og kohorte B)
Tidsramme: Uge 24
|
Uge 24
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Ændring i leverstivhed og Controlled Attenuation Parameter (CAP) af FibroScan. (Kohorte A og kohorte B i uge 24, kohorte A i uge 48)
Tidsramme: Uge 24 og 48
|
Uge 24 og 48
|
|
Ændring i absolut kropsvægt (kohorte A og B i uge 24, kohorte A i uge 48)
Tidsramme: Uge 24 og 48
|
Uge 24 og 48
|
|
Ændring i aspartataminotransferase (AST) og alaninaminotransferase (ALT) (kohorte A og kohorte B i uge 6 og 24, kohorte A i uge 48)
Tidsramme: Uge 6, 24 og 48
|
Uge 6, 24 og 48
|
|
Ændring i HbA1c (kohorte A og B i uge 24, kohorte A i uge 48)
Tidsramme: Uge 24 og 48
|
Uge 24 og 48
|
|
Ændring i HOMA-IR (kohorte A og B i uge 24, kohorte A i uge 48)
Tidsramme: Uge 24 og 48
|
Uge 24 og 48
|
|
Ændring i plasmaglukose (kohorte A og B i uge 24, kohorte A i uge 48)
Tidsramme: Uge 24 og 48
|
Uge 24 og 48
|
|
Procent relativ ændring fra baseline i leverfedtindhold ved MRI-PDFF (kohorte A og B i uge 6 og 24, kohorte A i uge 48)
Tidsramme: Uge 6 og 24, uge 48
|
Uge 6 og 24, uge 48
|
|
Absolut ændring fra baseline i leverfedtindhold ved MRI-PDFF (kohorte A og B i uge 6 og 24, kohorte A i uge 48)
Tidsramme: Uge 6, 24, uge 48
|
Uge 6, 24, uge 48
|
|
Opløsning af steatohepatitis (defineret som en ballondannelsesgrad på 0 og en lobulær inflammationsgrad på ≤ 1) og ingen forværring af leverfibrose i uge 48 vurderet ved biopsi (kohorte A).
Tidsramme: Uge 48
|
Uge 48
|
|
Andel af patienter med mindst 2 point reduktion fra baseline i NAS (NAFLD aktivitetsscore) uden forværring af leverfibrose i uge 48 vurderet ved biopsi, med mindst 1 point reduktion i ballondannelse eller inflammation (kohorte A).
Tidsramme: Uge 48
|
Uge 48
|
|
Forbedring i leverfibrosestadiet med mindst 1 point (NASH CRN fibrose-score) fra baseline og ingen forværring af steatohepatitis i uge 48 vurderet ved biopsi (kohorte A).
Tidsramme: Uge 48
|
Uge 48
|
|
Change in lipids - total cholesterol, HDL, LDL, VLDL, TG, serum free fatty acids, (Cohort A and Cohort B at Week 24, Cohort A at Week 48)
Tidsramme: Week 24 and 48
|
Week 24 and 48
|
|
Proportion of patients with Baseline ALT > 30 U/L achieving a reduction from Baseline in ALT ≥ 17 U/L at Week 24 (Cohort A and Cohort B) and Week 48 (Cohort A).
Tidsramme: Week 24, Week 48
|
Week 24, Week 48
|
|
Change in ELF, (Cohort A and B at Week 24, Cohort A at Week 48)
Tidsramme: Week 24 and 48
|
Week 24 and 48
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: Kavita Juneja, MD, Corcept Therapeutics
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- CORT118335-862
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .